References
- Crook A, McEwen A. Genetic counselling and testing for neurodegenerative disorders using a proposed standard of practice for ALS/MND: diagnostic testing comes first. Eur J Hum Genet. 2022;30:394–5.
- NICE. Shared decision making, NICE guideline. June 17, 2021. Available at: https://www.nice.org.uk/guidance/ng197. Accessed November 27, 2023.
- Salmon K, Ross JP, Bertone V, Gobbo M, Anoja N, Karamchandani J, et al. The value of testing for ATXN2 intermediate repeat expansions in routine clinical practice for amyotrophic lateral sclerosis. Eur J Hum Genet. 2022;30:1205–7.
- Crook A, Jacobs C, Newton‐John T, McEwen A. Genetic counseling and diagnostic genetic testing for familial amyotrophic lateral sclerosis and/or frontotemporal dementia: a qualitative study of client experiences. J Genet Couns. 2022;31:1206–18.
- Bekker HL, Winterbottom AE, Gavaruzzi T, Finderup J, Mooney A. Decision aids to assist patients and professionals in choosing the right treatment for kidney failure. Clin Kidney J. 2023;16:i20–i38.
- De Oliveira HM, Soma A, Baker MR, Turner MR, Talbot K, Williams TL. A survey of current practice in genetic testing in amyotrophic lateral sclerosis in the UK and Republic of Ireland: implications for future planning. Amyotroph Lateral Scler Frontotemporal Degener. 2023;24:405–13.